Clinical Trial Update: EXOMIND (BTL-995) for the Reduction of Binge-eating [NA]

View source ↗

Summary

A completed clinical trial evaluating EXOMIND (BTL-995) for reducing binge eating. The study includes individuals with binge eating and binge-eating disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating
• Binge Eating Disorder

Drugs mentioned

• EXOMIND (BTL-995)

Snippet

Sponsor: BTL Industries Ltd. | Conditions: Binge Eating, Binge-Eating Disorder | NA | Status: COMPLETED